Dynamic Technology Lab Private LTD Arrowhead Pharmaceuticals, Inc. Transaction History

Dynamic Technology Lab Private LTD

$601 Million
Q4 2024

A detailed history of Dynamic Technology Lab Private LTD transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 19,142 shares of ARWR stock, worth $264,542. This represents 0.06% of its overall portfolio holdings.

Number of Shares

19,142

Holding current value

$264,542

% of portfolio

0.06%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$17.7 - $26.34 $338,813 - $504,200	19,142 New	19,142 $359,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $334,819 - $545,903	11,300 New	11,300 $374,000
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $172,298 - $313,782	-6,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $245,643 - $433,814	6,200 New	6,200 $286,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $290,148 - $422,251	-4,970 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $308,885 - $448,890	4,970 New	4,970 $411,000
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $71,960 - $220,920	-3,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $98,490 - $255,535	3,500 New	3,500 $222,000
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $520,686 - $860,939	-29,873 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$12.05 - $20.18 $77,373 - $129,575	-6,421 Reduced 17.69%	29,873 $548,000
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $389,797 - $714,991	36,294 New	36,294 $450,000
Q1 2018 May 14, 2018	SELL	$3.72 - $7.64 $78,867 - $161,975	-21,201 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$3.14 - $4.5 $66,571 - $95,404	21,201	21,201 $78,000

Others Institutions Holding ARWR

# of Institutions

303

Shares Held

95.7M

Call Options Held

523K

Put Options Held

493K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.46B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.

Account

Dynamic Technology Lab Private LTD Arrowhead Pharmaceuticals, Inc. Transaction History